EUVIMEDEUVIMED entdecken
Crossref

Alexithymia in Functional Defecation Disorder: The Incidence and the Effect on Treatment

Sai Nan Shi, Bin Bin Zhu, Mei Feng Wang, Lin Lin, Liu Qin Jiang iD

Journal of Digestive Diseases · 2025

DOI: 10.1111/1751-2980.13356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2025. Verfasst von Sai Nan Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Hauptthemen laut MEDLINE: Affective Symptoms, Constipation. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to investigate the prevalence of alexithymia in patients with functional defecation disorder (FDD) and its impact on treatment outcomes.

Methods

FDD patients who underwent high‐resolution anorectal manometry and balloon expulsion test were enrolled. Symptoms, anorectal function, and treatment efficacy were assessed at baseline and after 4‐week medication.

Results

Alexithymia was present in 29.5% of all 129 FDD patients. Compared to the non‐alexithymia group, the alexithymia group had higher baseline scores for the Patient Assessment of Constipation‐Symptoms (PAC‐SYM) (19.0 vs. 15.0, p = 0.03), Patient Assessment of Constipation‐Quality of Life (PAC‐QOL) (67.0 vs. 26.0, p < 0.001), Zung's Self‐Rating Anxiety Scale (SAS) (44.5 vs. 30.0, p < 0.001), and Self‐Rating Depression Scale (SDS) (48.0 vs. 33.0, p < 0.001). Moreover, the improvements in post‐treatment complete spontaneous bowel movements (CSBMs) (0.0 vs. 1.5, p = 0.041), PAC‐SYM (0.0 vs. −11.5, p < 0.001), PAC‐QOL (0.0 vs. −16.0, p < 0.001), SAS (0.0 vs. −1.0, p < 0.001), and SDS (0.0 vs. −3.0, p < 0.001) scores were less significant in the alexithymia group than in the non‐alexithymia group. A high Toronto Alexithymia Scale‐20 score was an independent risk factor for drug therapy failure in FDD patients (odds ratio 0.949, 95% confidence interval 0.919–0.980, p = 0.001).

Conclusion

Alexithymia is prevalent in FDD patients and significantly affects symptom severity, quality of life, mental state, and treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Affective SymptomsConstipationHumansFemaleMaleMiddle AgedAdultQuality of LifeIncidenceTreatment OutcomeManometryPrevalenceAged

Stichwörter der Autor:innen

affective symptomsfunctional defecation disorderquality of lifesymptom assessmenttreatment effects

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Department of Gastroenterology, Nantong Haimen People's Hospital, Nantong, Jiangsu Province, China.

ORCID-Profile: Liu Qin Jiang

Zitieren

APA

Shi, S. N., Zhu, B. B., Wang, M. F., Lin, L., & Jiang, L. Q. (2025). Alexithymia in Functional Defecation Disorder: The Incidence and the Effect on Treatment. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13356

Vancouver

Shi SN, Zhu BB, Wang MF, Lin L, Jiang LQ. Alexithymia in Functional Defecation Disorder: The Incidence and the Effect on Treatment. Journal of Digestive Diseases. 2025. doi:10.1111/1751-2980.13356

BibTeX
@article{Shi2025,
  author = {Shi, Sai Nan and Zhu, Bin Bin and Wang, Mei Feng and Lin, Lin and Jiang, Liu Qin},
  title = {Alexithymia in Functional Defecation Disorder: The Incidence and the Effect on Treatment},
  journal = {Journal of Digestive Diseases},
  year = {2025},
  doi = {10.1111/1751-2980.13356}
}
Kostenlos starten →